Elevated cancer-specific mortality among HIV-infected patients in the United States

Journal of Clinical Oncology

Volumn 33, Issue 21, 2015, Pages 2376-2383

  Coghill, Anna E ^a   Shiels, Meredith S ^a   Suneja, Gita ^b   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANUS CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORTALITY; NEOPLASM; PRIORITY JOURNAL; UNITED STATES; AGED; COMPLICATION; EPIDEMIOLOGY; MEDICAL RECORD; MIDDLE AGED; PATHOLOGY; REGISTER; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; REGISTRIES; RISK FACTORS; UNITED STATES;

EID: 84940508021     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.5967     Document Type: Article

References (41)

1. Grulich AE, van Leeuwen MT, Falster MO, et al: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370:59-67, 2007
2. Engels EA, Pfeiffer RM, Goedert JJ, et al: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20:1645-1654, 2006
3. Shiels MS, Cole SR, Kirk GD, et al: A metaanalysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52:611-622, 2009
4. Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728-736, 2008
5. Bedimo RJ, McGinnis KA, Dunlap M, et al: Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: Impact of immunosuppression. J Acquir Immune Defic Syndr 52:203-208, 2009
6. Ray M, Logan R, Sterne JA, et al: The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24:123-137, 2010
7. Eltom MA, Jemal A, Mbulaiteye SM, et al: Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94:1204-1210, 2002
8. Robbins HA, Shiels MS, Pfeiffer RM, et al: Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 28:881-890, 2014
9. Bruyand M, Thiébaut R, Lawson-Ayayi S, et al: Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 49:1109-1116, 2009
10. Guiguet M, Boué F, Cadranel J, et al: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 10:1152-1159, 2009
11. Kesselring A, Gras L, Smit C, et al: Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 52:1458-1465, 2011
12. Biggar RJ, Engels EA, Ly S, et al: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 39:293-299, 2005
13. Coghill A, Newcomb PA, Madeleine MM, et al: Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS 27:2933-2942, 2013
14. Bateganya MH, Stanaway J, Brentlinger PE, et al: Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: A retrospective study on the impact of HIV infection and its treatment. J Acquir Immune Defic Syndr 56:312-319, 2011
15. Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753-762, 2011
16. Simard EP, Pfeiffer RM, Engels EA: Mortality due to cancer among people with AIDS: A novel approach using registry-linkage data and population attributable risk methods. AIDS 26:1311-1318, 2012
17. Suneja G, Shiels MS, Melville SK, et al: Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 27:459-468, 2013
18. Suneja G, Shiels MS, Angulo R, et al: Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 32:2344-2350, 2014
19. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al: Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306:1891-1901, 2011
20. Naito Y, Saito K, Shiiba K, et al: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491-3494, 1998
21. Pagès F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666, 2005
22. Clemente CG, Mihm MC Jr, Bufalino R, et al: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310, 1996
23. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
24. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
25. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
26. Kalos M, Levine BL, Porter DL, et al: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73, 2011
27. Kochenderfer JN, Dudley ME, Feldman SA, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720, 2012
28. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
29. Barillari G, Sgadari C, Fiorelli V, et al: The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 94:663-672, 1999
30. Barillari G, Sgadari C, Palladino C, et al: Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 163:1929-1935, 1999
31. Nyagol J, De Falco G, Lazzi S, et al: HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop 1:3-10, 2008
32. Sigel K, Crothers K, Dubrow R, et al: Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer 109:1974-1980, 2013
33. Chao C, Xu L, Abrams D, et al: Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS 24:1765-1770, 2010
34. Xicoy B, Ribera JM, Miralles P, et al: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 92:191-198, 2007
35. Spina M, Carbone A, Vaccher E, et al: Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 38:142-144, 2004
36. Antinori A, Cingolani A, Alba L, et al: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15:1483-1491, 2001
37. Achenbach CJ, Cole SR, Kitahata MM, et al: Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 25:691-700, 2011
38. Gopal S, Patel MR, Yanik EL, et al: Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 105:1221-1229, 2013
39. Shiels MS, Koritzinsky EH, Clarke CA, et al: Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev 23:274-281, 2014
40. Lau B, Cole SR, Gange SJ: Competing risk regression models for epidemiologic data. Am J Epidemiol 170:244-256, 2009
41. Simard EP, Engels EA: Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 51:957-962, 2010